Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Hannah Warren, Aleksandra Rautio, Laura Marandino, Nikolaos Pyrgidis, Lazaros Tzelves, Eduard Roussel, Stijn Muselaers, Selcuk Erdem, Carlotta Palumbo, Daniele Amparore, Zhenjie Wu, Chiara Ciccarese, Pietro Diana, Leonardo Borregales, Nicola Pavan, Angela Pecoraro, Anna Caliò, Tobias Klatte, Umberto Carbonara, Michele Marchioni, Riccardo Bertolo, Riccardo Campi, Maxine G B Tran
BACKGROUND AND OBJECTIVE: Renal tumour biopsy (RTB) can help in risk stratification of renal tumours with implications for management, but its utilisation varies. Our objective was to report current practice patterns, experiences, and perceptions of RTB and research gaps regarding RTB for small renal masses (SRMs). METHODS: Two web-based surveys, one for health care providers (HCPs) and one for patients, were distributed via the European Association of Urology Young Academic Urologist Renal Cancer Working Group and the European Society of Residents in Urology in January 2023...
April 2024: European urology open science
#22
REVIEW
Christopher Berridge, Altan Omer, Francisco Lopez, Richard J Bryant, Alastair D Lamb
For many years, transrectal ultrasound-guided (TRUS) prostate biopsies have been performed to establish a histological diagnosis of prostate cancer. This has been the recommended standard of care procedure, but has always carried risks, in particular the risk of post-procedural sepsis, and the associated antibiotic burden and risk of development of antibiotic resistance. Transperineal (TP) prostate biopsies performed under local anaesthetic (LA) have been proposed as a possible solution to these issues, with potentially lower infectious complications, and avoidance of need for antibiotic prophylaxis...
April 8, 2024: BJU International
#23
JOURNAL ARTICLE
Andrei Gafita, Andrew J Martin, Louise Emmett, Matthias Eiber, Amir Iravani, Wolfgang P Fendler, James Buteau, Shahneen Sandhu, Arun A Azad, Ken Herrmann, Martin R Stockler, Ian D Davis, Michael S Hofman
BACKGROUND: Prognostic models have been developed using data from a multicentre noncomparative study to forecast the likelihood of a 50% reduction in prostate-specific antigen (PSA50), longer prostate-specific antigen (PSA) progression-free survival (PFS), and longer overall survival (OS) in patients with metastatic castration-resistant prostate cancer receiving [177 Lu]Lu-PSMA radioligand therapy. The predictive utility of the models to identify patients likely to benefit most from [177 Lu]Lu-PSMA compared with standard chemotherapy has not been established...
April 6, 2024: European Urology Oncology
#24
JOURNAL ARTICLE
Robert J Motzer, Toni K Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A Lalani, Eric Winquist, Masatoshi Eto, Naveen S Basappa, Nizar M Tannir, Ulka Vaishampayan, Georg A Bjarnason, Stéphane Oudard, Viktor Grünwald, Joseph Burgents, Ran Xie, Jodi McKenzie, Thomas Powles
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis. Tumor responses were assessed by independent review using Response Evaluation Criteria in Solid Tumors v1...
April 5, 2024: European Urology
#25
JOURNAL ARTICLE
Georges Gebrael, Luis Meza, Xiaochen Li, Zeynep Zengin, Nicolas Sayegh, Hedyeh Ebrahimi, Nishita Tripathi, Daniela Castro, Benjamin Mercier, Regina Barragan-Carrillo, Haoran Li, Alexander Chehrazi-Raffle, Umang Swami, Abhishek Tripathi, Neeraj Agarwal, Benjamin L Maughan, Sumanta K Pal
BACKGROUND AND OBJECTIVE: The impact of time of metastasis onset with respect toprimary renal cell carcinoma (RCC) diagnosis on survival outcomes is not well characterized in the era of immune checkpoint inhibitor (ICI)-based combinations. Herein, we assessed differences in clinical outcomes between synchronous and metachronous metastatic RCC (mRCC). METHODS: Data for patients with mRCC treated with first-line ICI-based combination therapies between 2014 and 2023 were retrospectively collected...
April 4, 2024: European Urology Focus
#26
JOURNAL ARTICLE
Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Weiva Sieh, Kristina Sundquist
BACKGROUND: Men diagnosed with prostate cancer (PC) have an increased risk of depression; however, it is unclear to what extent depression affects long-term survival. A better understanding of such effects is needed to improve long-term care and outcomes for men with PC. OBJECTIVE: To determine the associations between major depression and mortality in a national cohort of men with PC. DESIGN, SETTING, AND PARTICIPANTS: A national cohort study was conducted of all 180 189 men diagnosed with PC in Sweden during 1998-2017...
April 3, 2024: European Urology Oncology
#27
JOURNAL ARTICLE
Aleksandar Trifunovski, Galina Severova, Ana Atanasova, Josif Janculev, Viktor Stankov, Sotir Stavridis, Skender Saidi, Aleksandra Gavrilovska Brzanov, Martina Ambardjieva, Sasho Dohchev
INTRODUCTION: Obstructive uropathy encompasses various urinary tract obstructions, leading to changes in urine flow, kidney pressure, and impaired kidney function. Predicting renal recovery from obstructive uropathy, can be challenging and necessitates treatment, as in percutaneous nephrostomy (PNS) drainage. The choice of drainage method depends on patient-specific factors and local expertise. According to the data for the Republic of North Macedonia, in the register of the European Renal Association, in the last few years, there has been an increase in the percentage of patients with obstructive nephropathy from 7...
March 1, 2024: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
#28
JOURNAL ARTICLE
Pawel Rajwa, Angelika Borkowetz, Thomas Abbott, Andrea Alberti, Anders Bjartell, James T Brash, Riccardo Campi, Andrew Chilelli, Mitchell Conover, Niculae Constantinovici, Eleanor Davies, Bertrand De Meulder, Sherrine Eid, Mauro Gacci, Asieh Golozar, Haroon Hafeez, Samiul Haque, Ayman Hijazy, Tim Hulsen, Andreas Josefsson, Sara Khalid, Raivo Kolde, Daniel Kotik, Samu Kurki, Mark Lambrecht, Chi-Ho Leung, Julia Moreno, Rossella Nicoletti, Daan Nieboer, Marek Oja, Soundarya Palanisamy, Peter Prinsen, Christian Reich, Giulio Raffaele Resta, Maria J Ribal, Juan Gómez Rivas, Emma Smith, Robert Snijder, Carl Steinbeisser, Frederik Vandenberghe, Philip Cornford, Susan Evans-Axelsson, James N'Dow, Peter-Paul M Willemse
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in the management of this disease stage. However, these therapies come with their fair share of toxicities and side effects. The goal of this observational study is to report drug-related adverse events (AEs), which are correlated with systemic combination therapies for mHSPC. Determining the optimal treatment option requires large cohorts to estimate the tolerability and AEs of these combination therapies in "real-life" patients with mHSPC, as provided in this study...
May 2024: European urology open science
#29
JOURNAL ARTICLE
Margaret F Meagher, Andrea Minervini, Maria C Mir, Clara Cerrato, Giacomo Rebez, Riccardo Autorino, Lance Hampton, Riccardo Campi, Maximilian Kriegmair, Estefania Linares, Vital Hevia, Maria Musquera, Mauricio D'Anna, Eduard Roussel, Maarten Albersen, Nicola Pavan, Francesco Claps, Alessandro Antonelli, Michele Marchioni, Nail Paksoy, Selcuk Erdem, Ithaar H Derweesh
BACKGROUND AND OBJECTIVE: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparative analyses of CN for patients treated with immuno-oncology (IO) versus TKI agents are sparse. Our objective was to compare CN timing and outcomes among patients who received TKI versus IO therapy. METHODS: This was a multicenter retrospective analysis of patients who underwent CN using data from the REMARCC (Registry of Metastatic RCC) database...
May 2024: European urology open science
#30
JOURNAL ARTICLE
Matthew P Deek, Philip Sutera, Yuezhou Jing, Robert Gao, Emily Rothman, Heather Day, David Chang, Piet Dirix, Andrew J Armstrong, Bethany Campbell, Fernando Lopez Campos, Miguel Berenguer, Matthew Ramotar, Antonio Conde-Moreno, Alejandro Berlin, Davide Giovanni Bosetti, Niall Corcoran, Bridget Koontz, Carole Mercier, Shankar Siva, David Pryor, Piet Ost, Mai Anh Huynh, Stephanie Kroeze, Bradley Stish, Ana Kiess, Bruce Trock, Phuoc T Tran, Silke Gillessen, Christopher Sweeney
BACKGROUND: Metastasis-directed therapy (MDT) is increasingly being used in oligometastatic castration-sensitive prostate cancer (omCSPC). However, it is currently unclear how to optimally integrate MDT with the standard of care of systemic hormonal therapy. OBJECTIVE: To report long-term outcomes of MDT alone versus MDT and a defined course of androgen deprivation therapy (ADT) in omCSPC. DESIGN, SETTING, AND PARTICIPANTS: Here, a multicenter, international retrospective cohort of omCSPC as defined by conventional imaging was reported...
April 2, 2024: European Urology Oncology
#31
JOURNAL ARTICLE
Sophie D Fosså, Anne Holck Storås, Kirsti Aas, Tom Børge Johannesen, Ylva Maria Gjelsvik, Tor Å Myklebust
BACKGROUND AND OBJECTIVE: Registry-based studies for prostate cancer (PCa) document higher overall mortality (OM) after high-dose radiotherapy (RT) than after radical prostatectomy (RP). Our aim was to explore the association between pretreatment patient-reported health ("OverallHealth": OH) and curative treatment type, and the impact on early OM. METHODS: New PCa patients registered between 2017 and 2019 in the Cancer Registry of Norway ( n = 1949) completed the European Organisation for Research and Treatment of Cancer Quality-of-Life Core 30 (QLQ-C30) questionnaire before RP ( n = 592) or RT ( n = 610) or after allocation to active surveillance (AS; n = 747)...
May 2024: European urology open science
#32
JOURNAL ARTICLE
Daniele Castellani, Dmitry Enikeev, Mehmet Ilker Gokce, Vladislav Petov, Nariman Gadzhiev, Abhay Mahajan, Pankaj Nandkishore Maheshwari, Khi Yung Fong, Azimdjon N Tursunkulov, Vigen Malkhasyan, Marek Zawadzki, Mario Sofer, Luigi Cormio, Gian Maria Busetto, Bhaskar Kumar Somani, Thomas R W Herrmann, Vineet Gauhar
BACKGROUND: The use of the new thulium fiber laser in enucleation of the prostate (ThuFLEP) has been introduced recently. OBJECTIVE: To evaluate complications and urinary incontinence (UI) after ThuFLEP in small and large prostate volume (PV). DESIGN SETTING AND PARTICIPANTS: We retrospectively reviewed patients who underwent ThuFLEP in six centers (from January 2020 to January 2023). The exclusion criteria were concomitant lower urinary tract surgery, previous prostate/urethral surgery, prostate cancer, and pelvic radiotherapy...
May 2024: European urology open science
#33
JOURNAL ARTICLE
Vérane Achard, Béatrice Fournier, David D'Haese, Joanna Krzystyniak, Bertrand Tombal, Morgan Roupret, Paul Sargos, Piet Dirix
Radical cystectomy with pelvic lymph node dissection and urinary diversion is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). However, many patients are unwilling or unable to undergo such major surgery associated with high morbidity and a negative impact on quality of life. Chemoradiotherapy is an established treatment option for muscle-invasive bladder cancer. However, it has not been investigated adequately in NMIBC until now...
March 30, 2024: European Urology Oncology
#34
JOURNAL ARTICLE
Riccardo Campi, Alessio Pecoraro, Federico Piramide, Maria Lucia Gallo, Sergio Serni, Alex Mottrie, Angelo Territo, Karel Decaestecker, Alberto Breda
PURPOSE: Robot-assisted kidney transplantation (RAKT) is being increasingly performed at selected referral institutions worldwide. Yet, surgical training in RAKT is still unstructured and not grounded into formal credentialing courses including simulation, lab facilities, and modular training with animal models. As such, developing standardized, modular training programs is warranted to provide surgeons with the RAKT-specific skillset needed for a "safe" learning curve. METHODS: The 3-day course on RAKT developed at the EAU Skills Center in Orsi Academy was designed as a standardized, modular, step-by-step approach aiming to provide theoretical and practical skills...
March 30, 2024: World Journal of Urology
#35
REVIEW
Savio Domenico Pandolfo, Simone Cilio, Achille Aveta, Zhenjie Wu, Clara Cerrato, Luigi Napolitano, Francesco Lasorsa, Giuseppe Lucarelli, Paolo Verze, Salvatore Siracusano, Carmelo Quattrone, Matteo Ferro, Eugenio Bologna, Riccardo Campi, Francesco Del Giudice, Riccardo Bertolo, Daniele Amparore, Sara Palumbo, Celeste Manfredi, Riccardo Autorino
BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare disease with a potentially dismal prognosis. We systematically compared international guidelines on UTUC to analyze similitudes and differences among them. METHODS: We conducted a search on MEDLINE/PubMed for guidelines related to UTUC from 2010 to the present. In addition, we manually explored the websites of urological and oncological societies and journals to identify pertinent guidelines. We also assessed recommendations from the International Bladder Cancer Network, the Canadian Urological Association, the European Society for Medical Oncology, and the International Consultation on Bladder Cancer, considering their expertise and experience in the field...
March 11, 2024: Cancers
#36
JOURNAL ARTICLE
Katia Vanolli, Mike Libasse Jost, Olivier Clerc, Daniel Genné, Gregor John
Recent European Association of Urology (EAU) guidelines and a clinical prediction rule developed by Van Nieuwkoop et al. suggest simple criteria for performing radiological imaging for patients with a febrile urinary tract infection (UTI). We analysed the records of patients with a UTI from four hospitals in Switzerland. Of 107 UTI patients, 58% underwent imaging and 69% (95%CI: 59-77%) and 64% (95%CI: 54-73%) of them were adequately managed according to Van Nieuwkoop's clinical rule and EAU guidelines, respectively...
February 23, 2024: Infectious Disease Reports
#37
EDITORIAL
John Heesakkers, Frans Debruyne, David Castro Diaz
No abstract text is available yet for this article.
May 2024: European urology open science
#38
JOURNAL ARTICLE
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather H Cheng, Benjamin L Maughan, Jingsong Zhang, Russell K Pachynski, Alan H Bryce, Daniel W Lin, David I Quinn, Seth P Lerner, Ian M Thompson, Tanya B Dorff, Primo N Lara, Neeraj Agarwal
BACKGROUND: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC) since 2006, but the treatment of mHSPC has since evolved to include intensified therapy. OBJECTIVE: We assessed the association of PSA levels at 3 (PSA-3mo) and 7 (PSA-7mo) mo with overall survival (OS) in patients with mHSPC treated with ADT combined with either bicalutamide or orteronel in the S1216 phase 3 clinical trial...
March 23, 2024: European Urology Oncology
#39
JOURNAL ARTICLE
Reuben Ben-David, Neeraja Tillu, Shivaram Cumarasamy, Parissa Alerasool, Jordan M Rich, Basil Kaufmann, Yuval Elkun, Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P Sfakianos
BACKGROUND AND OBJECTIVE: Decision-making on the use of neoadjuvant and adjuvant treatment for patients with bladder cancer undergoing radical cystectomy (RC) currently depends on assessment of clinical and pathological features, which lack sensitivity. Circulating tumor DNA (ctDNA) has emerged as a possible novel prognostic biomarker in the field. Our aim was to assess whether ctDNA status before RC is predictive of pathological and oncological outcomes. We also evaluated the dynamic changes in ctDNA status after RC in relation to recurrence-free survival (RFS)...
March 22, 2024: European Urology Oncology
#40
JOURNAL ARTICLE
Laura García-Zoghby, Mariano Amo-Salas, Ángel María Soriano Castrejón, Ana María García Vicente
PURPOSE: The objective was to assess the association between molecular imaging (mi) variables on [18F]DCFPyL-PET/CT with clinical and disease characteristics and prostate specific antigen (PSA) related variables in patients with biochemical recurrence of prostate cancer (BRPC). MATERIAL AND METHODS: We analysed patients with BRPC after radical treatment. We obtained clinical and PSA variables: International Society of Urology Pathology (ISUP) grade group, European Association of Urology (EAU) risk classification, PSA (PSA≤1ng/ml, 1<PSA≤2, PSA>2), PSA doubling time (PSAdt) and PSA velocity (PSAvel)...
March 23, 2024: European Journal of Nuclear Medicine and Molecular Imaging
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
